Please login to the form below

Not currently logged in
Email:
Password:

Kanuma

This page shows the latest Kanuma news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy

With patents due to expire in the US and Europe in the next three years – and new drugs such as lysosomal acid lipase deficiency treatment Kanuma and Strensiq for hypophosphatasia still

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    This agreement brings access to Kanuma (sebelipase alfa) which is in registration for the treatment of lysosomal acid lipase (LAL) deficiency. ... Corporate acquisition. Rare diseases portfolio including Kanuma (sebelipase alpha) for LAL deficiency.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics